Ariel G. Kann

Sao Paulo, SP, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.

Journal: The Journal of urology

Published: October 09, 2025

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Journal: The New England journal of medicine

Published: September 16, 2024

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

Journal: JACC. CardioOncology

Published: February 18, 2024

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.

Journal: Lancet (London, England)

Published: August 11, 2022

"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".

"Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil".

Journal: Clinical genitourinary cancer

Published: May 09, 2022

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis.

The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis.

Journal: JACC. CardioOncology

Published: April 25, 2022

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC).

Journal: JCO global oncology

Published: April 15, 2021

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries.

Journal: JCO global oncology

Published: April 15, 2021

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Journal: Medical oncology (Northwood, London, England)

Published: December 04, 2014

Showing 1-10 of 10

Last Updated: 09/26/2026